Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ekso Bionics Holdings Inc EKSO

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.


NDAQ:EKSO - Post by User

Post by AviseAnalyticson Jul 24, 2024 8:54am
34 Views
Post# 36145842

EKSO BIONICS: ADVANCING RAPIDLY IN THE EXOSKELETON INDUSTRY

EKSO BIONICS: ADVANCING RAPIDLY IN THE EXOSKELETON INDUSTRY

$EKSO

Excited to share an article about  Ekso Bionics Holdings, Inc., an industry leader in exoskeleton technology for medical and industrial use.

For FY23, Ekso achieved record revenue of $18.3 mn, compared to $12.9 mn for FY22, an increase of 42% YoY. The Company has significant opportunities in the markets it serves. Specifically, its Health segment has an annual global market opportunity of at least $650 mn - $900 mn, while the Works segment presents an annual opportunity of more than $5 bn.

Ekso's recent record revenue growth and significant market opportunity make the Company an interesting watch.

Read on to know more:

https://www.aviseanalytics.com/ekso-bionics-advancing-rapidly-in-the-exoskeleton-industry/

<< Previous
Bullboard Posts
Next >>